The DOI matches its Crossref record; 45 of the 45 references it cites were found in a registry or an index.
Cognitive Enhancers as Adjuncts to Psychotherapy: Use of D-Cycloserine in Phobic Individuals to Facilitate Extinctionof Fear
Abstract
BACKGROUND: Traditional pharmacological approaches to treating psychiatric disorders focus on correcting presumed biochemical abnormalities. However, some disorders, particularly the anxiety-related disorders exemplified by specific phobia, have an emotional learning component to them that can be facilitated with psychotherapy. OBJECTIVE: To determine whether D-cycloserine (DCS), a partial agonist at the N-methyl-d-aspartate receptor that has previously been shown to improve extinction of fear in rodents, will also improve extinction of fear in human phobic patients undergoing behavioral exposure therapy. DESIGN: Randomized, double-blind, placebo-controlled trial examining DCS vs placebo treatment in combination with a precisely controlled exposure paradigm. SETTING: Participants were recruited from the general community to a research clinic. PARTICIPANTS: Twenty-eight subjects with acrophobia diagnosed by the Structured Clinical Interview for DSM-IV were enrolled. INTERVENTIONS: After we obtained pretreatment measures of fear, subjects were treated with 2 sessions of behavioral exposure therapy using virtual reality exposure to heights within a virtual glass elevator. Single doses of placebo or DCS were taken prior to each of the 2 sessions of virtual reality exposure therapy. Subjects, therapists, and assessors were blind to the treatment condition. Subjects returned at 1 week and 3 months posttreatment for measures to determine the presence and severity of acrophobia symptoms. MAIN OUTCOME MEASURES: Included were measures of acrophobia within the virtual environment, measures of acrophobia in the real world, and general measures of overall improvement. An objective measure of fear, electrodermal skin fluctuation, was also included during the virtual exposure to heights. Symptoms were assessed by self-report and by independent assessors at approximately 1 week and 3 months posttreatment. RESULTS: Exposure therapy combined with DCS resulted in significantly larger reductions of acrophobia symptoms on all main outcome measures. Subjects receiving DCS had significantly more improvement compared with subjects receiving placebo within the virtual environment (1 week after treatment, P</=.001; 3 months later, P</=.05). Subjects receiving DCS also showed significantly greater decreases in posttreatment skin conductance fluctuations during the virtual exposure (P</=.05). Additionally, subjects receiving DCS had significantly greater improvement compared with subjects receiving placebo on general measures of real-world acrophobia symptoms (acrophobia avoidance [P</=.02], acrophobia anxiety [P</=.01], attitudes toward heights [P</=.04], clinical global improvement [P</=.01], and number of self-exposures to real-world heights [P</=.01]); the improvement was evident early in treatment and was maintained at 3 months. CONCLUSION: These pilot data provide initial support for the use of acute dosing of DCS as an adjunct to exposure-based psychotherapy to accelerate the associative learning processes that contribute to correcting psychopathology.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“DCS is an agonist of the N-methyl-D-aspartate (NMDA) glutamate receptor, and it has been shown to increase the efficacy of exposure therapies for a number of anxiety disorders (Hofmann, Sawyer, and Asnaani, 2012; Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004).”
From Advancing the treatment of anxiety disorders in transition‐age youth: a review of the therapeutic effects of unconscious exposure. (2025) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, et al. 2004
In the citing paper
“Participants who received the drug (oral administration two to four hours before each session) showed greater improvements than those who received a placebo.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“The effects were evident one week and three months after treatment.”
From Mediators and Mechanisms of Change in Psychotherapy Research (2007) · cites this paper as Ressler et al. 2004
In the citing paper
“Recently, DCS combined with imaginal or virtual reality exposure (VRE) therapy has been shown to reduce length of treatment for some anxiety disorders, including acrophobia (Ressler et al, 2004), social phobia (Guastella et al, 2008; Hofmann et al, 2006), and panic disorder (Otto et al, 2010), which, like PTSD, include learned avoidance and cued emotional distress as salient symptoms.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“The choice of dosing regimen for our studies was based on the Ressler et al (2004) study, which showed that there was no difference in efficacy between the 50 and 500 mg dose of DCS on enhancing exposure therapy outcomes.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al (2004)
In the citing paper
“We chose weekly dosing, administered 90 min before exposure sessions, as this regimen has been effective in multiple animal and human fear extinction studies (Ledgerwood et al, 2003; Ressler et al, 2004; Walker et al, 2002)”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“These pilot data add to the literature showing that DCS-enhanced exposure therapy is effective for the treatment of anxiety disorders (Hofmann et al, 2006; Ressler et al, 2004).”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Our data, in conjunction with that of Ressler et al (2004), Hofmann et al (2006), and Otto et al (2010), form a compelling pattern of evidence supporting the hypothesis that DCS may facilitate extinction learning.”
From D-cycloserine augmentation of exposure therapy for post-traumatic stress disorder: a pilot randomized clinical trial (2014) · cites this paper as Ressler et al, 2004
In the citing paper
“Shortly thereafter, several groups reported that DCS administration before or after exposure therapy, a form of treatment based on the principles of fear extinction learning, was effective in alleviating the symptoms of acrophobia (67), panic disorder (68), social anxiety disorder (69, 70), and obsessive–compulsive disorder (71–73).”
From Conditioned fear associated phenotypes as robust, translational indices of trauma-, stressor-, and anxiety-related behaviors (2014) · cites this paper as [67]
In the citing paper
“The rationale for selecting 50 mg as the dose was that this dose showed efficacy in previous work examining exposure enhancement with pre-session administration of DCS (10, 11).”
From D-cycloserine enhancement of fear extinction is specific to successful exposure sessions: evidence from the treatment of height phobia (2013) · cites this paper as [10]
In the citing paper
“In humans, DCS administration can likewise facilitate the loss of fear resulting from exposure that causes incomplete fear loss in controls (acrophobia: Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004; social phobia: Guastella, Richardson, Lovibond, Rapee, Gaston, Mitchell, & Dadds, 2008; Hofmann, Meuret, Smits, Simon, Pollack, Eisenmenger, Shiekh, & Otto, 2006;”
From D-cycloserine facilitates context-specific fear extinction learning (2008) · cites this paper as Ressler, Rothbaum, Tannenbaum, Anderson, Graap, Zimand, Hodges, & Davis, 2004
In the citing paper
“Indeed, in clinical studies, Ressler et al (2004) and Hofmann et al (2006) have recently reported that DCS facilitates fear extinction in patients with anxiety disorders.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“This, considered collectively with findings from animal studies, leads to the postulation that DCS administration without extinction training cannot facilitate fear extinction.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al, 2004
In the citing paper
“Heresco-Levy et al (2002) used daily chronic dosing without exposure therapy, while Hofmann et al (2006) and Ressler et al (2004) used acute dosing with exposure therapy.”
From Effects of Single Prolonged Stress and D-Cycloserine on Contextual Fear Extinction and Hippocampal NMDA Receptor Expression in a Rat Model of PTSD (2008) · cites this paper as Ressler et al (2004)
Citations
Cites
An inventory for measuring depression
BECK, A. T. (1961) · Archives of General Psychiatry · doi:10.1001/archpsyc.1961.01710120031004 · Cited by 38,032
The Structured Clinical Interview for DSM-III-R (SCID): I: History, Rationale, and Description
Spitzer, R. L. (1992) · Archives of General Psychiatry · doi:10.1001/archpsyc.1992.01820080032005 · Cited by 4,336
Manual for the state-trait anxiety inventory (form Y) : "self-evaluation questionnaire"
Spielberger, C. D., Gorsuch, R. L., & Lushene, R. E. (1970) · Consulting Psychologists Press eBooks · Cited by 2,352
Genetic enhancement of learning and memory in mice
Tang, Y., Shimizu, E., Dubé, G., Rampon, C., Kerchner, G. A., Zhuo, M., Liu, G., & Tsien, J. Z. (1999) · Nature · doi:10.1038/43432 · Cited by 1,878
Context, ambiguity, and unlearning: sources of relapse after behavioral extinction
Bouton, M. E. (2002) · Biological Psychiatry · doi:10.1016/s0006-3223(02)01546-9 · Cited by 1,662
Barlow, D. H., Gorman, J. M., Shear, M. K., & Woods, S. W. (2000) · JAMA · doi:10.1001/jama.283.19.2529 · Cited by 953
Behavioral and Neural Analysis of Extinction
Myers, K. M., & Davis, M. (2002) · Neuron · doi:10.1016/s0896-6273(02)01064-4 · Cited by 918
Self-citationMiserendino, M. J. D., Sananes, C. B., Melia, K. R., & Davis, M. (1990) · Nature · doi:10.1038/345716a0 · Cited by 824
Self-citationWalker, D. L., Ressler, K. J., Lu, K.-T., & Davis, M. (2002) · The Journal of Neuroscience · doi:10.1523/jneurosci.22-06-02343.2002 · Cited by 815
Self-citationEffectiveness of computer-generated (virtual reality) graded exposure in the treatment of acrophobia
(1995) · American Journal of Psychiatry · doi:10.1176/ajp.152.4.626 · Cited by 694
Self-citation
Cited by
Sorted by citations
Items 501–600 of 1,000
Pharmacological enhancement of drug cue extinction learning: translational challenges
Kantak, K. M., & Dhonnchadha, B. Á. N. (2011) · Annals of the New York Academy of Sciences · doi:10.1111/j.1749-6632.2010.05899.x · Cited by 35
Byrne, S., Haber, P., Baillie, A., Giannopolous, V., & Morley, K. C. (2019) · Substance Use & Misuse · doi:10.1080/10826084.2019.1618328 · Cited by 37
Pharmacotherapy of panic disorder
Pull, C. (2008) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s1224 · Cited by 32
Norrholm, S. D., Anderson, K. M., Olin, I. W., Jovanovic, T., Kwon, C., Warren, V. T., McCarthy, A., Bosshardt, L., Sabree, J., Duncan, E. J., et al. (2011) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2011.00077 · Cited by 34
Self-citationPsychosocial interventions for adults with crime-related PTSD.
Amstadter, A. B., McCart, M. R., & Ruggiero, K. J. (2007) · Professional Psychology Research and Practice · doi:10.1037/0735-7028.38.6.640 · Cited by 34
Krystal, J. H. (2007) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.08.017 · Cited by 34
Non-invasive neurophysiological measures of learning: A meta-analysis
Tinga, A. M., de Back, T. T., & Louwerse, M. M. (2019) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2019.02.001 · Cited by 37
Modulatory effects of an NMDAR partial agonist in MK-801-induced memory impairment
Vishnoi, S., Raisuddin, S., & Parvez, S. (2015) · Neuroscience · doi:10.1016/j.neuroscience.2015.10.008 · Cited by 35
Monte, F. H. D., Allensworth, M. L., & Carobrez, A. P. (2010) · Behavioural Brain Research · doi:10.1016/j.bbr.2010.03.014 · Cited by 35
Lin, H., Mao, S.-C., Su, C.-L., & Gean, P. (2009) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145709990678 · Cited by 34
Naim, R., Dombek, K., German, R. E., Haller, S. P., Kircanski, K., & Brotman, M. A. (2023) · Journal of Clinical Child & Adolescent Psychology · doi:10.1080/15374416.2023.2264385 · Cited by 33
D-CYCLOSERINE ENHANCES GENERALIZATION OF FEAR EXTINCTION IN CHILDREN
Byrne, S., Rapee, R. M., Richardson, R., Malhi, G. S., Jones, M., & Hudson, J. L. (2015) · Depression and Anxiety · doi:10.1002/da.22356 · Cited by 33
Watson, B. J., Wilson, S., Griffin, L., Kalk, N. J., Taylor, L. G., Munafo, M. R., Lingford-Hughes, A. R., & Nutt, D. (2011) · Psychopharmacology · doi:10.1007/s00213-011-2199-2 · Cited by 33
Implications of the Research Domain Criteria project for childhood anxiety and its disorders
Lebowitz, E. R., Gee, D. G., Pine, D. S., & Silverman, W. K. (2018) · Clinical Psychology Review · doi:10.1016/j.cpr.2018.01.005 · Cited by 35
Gruenbaum, B. F., Kutz, R., Zlotnik, A. A., & Boyko, M. (2020) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125320903951 · Cited by 32
Cornwell, B., Heller, R., Biggs, A. L., Pine, D., & Grillon, C. (2010) · Journal of Clinical Psychiatry · doi:10.4088/jcp.09m05731blu · Cited by 40
Assessment and Treatment of Anxiety Disorders in Children and Adolescents
Connolly, S. D., Suárez, L., & Sylvester, C. E. (2011) · Current Psychiatry Reports · doi:10.1007/s11920-010-0173-z · Cited by 36
Hamm, A. O. (2009) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2009.05.008 · Cited by 33
Yen, Y.-C., Mauch, C. P., Dahlhoff, M., Micale, V., Bunck, M., Sartori, S. B., Singewald, N., Landgraf, R., & Wotjak, C. T. (2012) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2012.04.009 · Cited by 31
de Kleine, R. A., Smits, J. A. J., Hendriks, G., Becker, E. S., & van Minnen, A. (2015) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2015.06.005 · Cited by 33
Dose Timing of D -Cycloserine to Augment Exposure Therapy for Social Anxiety Disorder
Smits, J. A. J., Pollack, M. H., Rosenfield, D., Otto, M. W., Dowd, S. M., Carpenter, J. K., Dutcher, C. D., Lewis, E. M., Witcraft, S. M., Papini, S., et al. (2020) · JAMA Network Open · doi:10.1001/jamanetworkopen.2020.6777 · Cited by 32
Models of PTSD and traumatic stress: the importance of research “from bedside to bench to bedside”
Ursano, R. J., Li, H., Zhang, L., Hough, C., Fullerton, C. S., Benedek, D. M., Grieger, T. A., & Holloway, H. C. (2007) · Progress in brain research · doi:10.1016/s0079-6123(07)67014-9 · Cited by 34
Extinction: New Excitement for an Old Phenomenon
Quirk, G. J. (2006) · Biological Psychiatry · doi:10.1016/j.biopsych.2006.05.023 · Cited by 32
D-Cycloserine enhances memory consolidation of hippocampus-dependent latent extinctionPreprint
Gabriele, A., & Packard, M. G. (2007) · Learning & Memory · doi:10.1101/lm.528007 · Cited by 32
Dai, J., & Zhou, H. (2014) · Structure · doi:10.1016/j.str.2014.11.012 · Cited by 31
Using virtual reality to help our patients in the real world
ROTHBAUM, B. O. (2009) · Depression and Anxiety · doi:10.1002/da.20556 · Cited by 31
Self-citationGupta, S. C., Hillman, B. G., Prakash, A., Ugale, R. R., Stairs, D. J., & Dravid, S. M. (2013) · European Journal of Neuroscience · doi:10.1111/ejn.12197 · Cited by 31
New approaches to combining pharmacotherapy and psychotherapy for posttraumatic stress disorder
Pratchett, L. C., Daly, K. A., Bierer, L. M., & Yehuda, R. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.604030 · Cited by 31
Amphetamine Enhances Gains in Auditory Discrimination Training in Adult Schizophrenia Patients
Swerdlow, N. R., Tarasenko, M. A., Bhakta, S. G., Talledo, J., Álvarez, A., Hughes, E., Rana, B. K., Vinogradov, S., & Light, G. A. (2016) · Schizophrenia Bulletin · doi:10.1093/schbul/sbw148 · Cited by 30
Goodman, J., Ressler, R. L., & Packard, M. G. (2017) · Neuroscience · doi:10.1016/j.neuroscience.2017.03.042 · Cited by 29
Manfro, G. G., Heldt, E., Cordioli, A. V., & Otto, M. W. (2008) · DOAJ (DOAJ: Directory of Open Access Journals) · doi:10.1590/s1516-44462008000600005 · Cited by 1
Psychotherapy for obsessive-compulsive disorder
Storch, E. A., Mariaskin, A., & Murphy, T. K. (2009) · Current Psychiatry Reports · doi:10.1007/s11920-009-0043-8 · Cited by 30
Jacquart, J., Roquet, R. F., Papini, S., Powers, M. B., Rosenfield, D., Smits, J. A. J., & Monfils, M. (2017) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2017.05.010 · Cited by 35
Effects of d -Cycloserine on Craving to Alcohol Cues in Problem Drinkers: Preliminary Findings
Hofmann, S. G., Hüweler, R., MacKillop, J., & Kantak, K. M. (2011) · The American Journal of Drug and Alcohol Abuse · doi:10.3109/00952990.2011.600396 · Cited by 29
Dillon, D. G., Deveney, C. M., & Pizzagalli, D. A. (2011) · Emotion Review · doi:10.1177/1754073910380973 · Cited by 32
The effect of repetitive transcranial magnetic stimulation on fear extinction in rats.
Baek, K., Chae, J.-H., & Jeong, J.-W. (2012) · Neuroscience · doi:10.1016/j.neuroscience.2011.09.050 · Cited by 29
Drexler, S. M., Hamacher‐Dang, T. C., & Wolf, O. T. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.04.002 · Cited by 32
d-Cycloserine facilitates extinction learning and enhances extinction-related brain activation
Klass, A., Glaubitz, B., Tegenthoff, M., & Lissek, S. (2017) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2017.08.003 · Cited by 30
Pharmacological Augmentation of Psychosocial and Remediation Training Efforts in Schizophrenia
Harvey, P. D., & Sand, M. S. (2017) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2017.00177 · Cited by 29
Meduri, J. D., Farnbauch, L. A., & Jasnow, A. M. (2013) · Behavioural Brain Research · doi:10.1016/j.bbr.2013.09.009 · Cited by 28
Nawreen, N., Baccei, M. L., & Herman, J. P. (2021) · Frontiers in Cellular Neuroscience · doi:10.3389/fncel.2021.705660 · Cited by 29
Prisciandaro, J. J., Myrick, H., Henderson, S., McRae‐Clark, A. L., Ana, E. J. S., Saladin, M. E., & Brady, K. T. (2013) · Drug and Alcohol Dependence · doi:10.1016/j.drugalcdep.2013.02.009 · Cited by 30
Attari, A., Rajabi, F., & Maracy, M. R. (2014) · PubMed Central · Cited by 28
Birk, L. (2004) · Journal of Clinical Psychology · doi:10.1002/jclp.20044 · Cited by 31
Neuroenhancement of Exposure Therapy in Anxiety Disorders
Hofmann, S. G., Mundy, E. A., & Curtiss, J. E. (2015) · AIMS neuroscience · doi:10.3934/neuroscience.2015.3.123 · Cited by 27
Yamamoto, S., Morinobu, S., Iwamoto, Y., Ueda, Y., Takei, S., Fujita, Y., & Yamawaki, S. (2010) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2010.03.013 · Cited by 31
Bolkan, S. S., & Lattal, K. M. (2014) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2013.12.009 · Cited by 28
Yoon, J. H., Newton, T. F., Haile, C. N., Bordnick, P. S., Fintzy, R., Culbertson, C., Mahoney, J. J., Hawkins, R. Y., LaBounty, K. R., Ross, E. L., et al. (2012) · Addictive Behaviors · doi:10.1016/j.addbeh.2012.03.022 · Cited by 27
The role of the dorsal striatum in extinction: A memory systems perspective
Goodman, J., & Packard, M. G. (2018) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2018.02.028 · Cited by 30
Markowitz, S., & Fanselow, M. S. (2020) · Brain Sciences · doi:10.3390/brainsci10030167 · Cited by 28
Competing Visions of the Implications of Neuroscience for Psychotherapy
Toomey, B., & Ecker, B. (2009) · Journal of Constructivist Psychology · doi:10.1080/10720530802675748 · Cited by 31
Epigenetic mechanisms underlying extinction of memory and drug-seeking behavior
Malvaez, M., Barrett, R. M., Wood, M. A., & Sanchis‐Segura, C. (2009) · Mammalian Genome · doi:10.1007/s00335-009-9224-3 · Cited by 27
Amphetamine and extinction of cued fear
Carmack, S. A., Wood, S. C., & Anagnostaras, S. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.10.049 · Cited by 27
Fujihira, T., Kanematsu, S., Umino, A., Yamamoto, N., & Nishikawa, T. (2007) · Neurochemistry International · doi:10.1016/j.neuint.2007.06.003 · Cited by 27
Method development studies for repeatedly measuring anxiolytic drug effects in healthy humans
Klumpers, F., van Gerven, J., Prinssen, E., Niklson Roche, I., Roesch, F., Riedel, W., Kenemans, J., & Baas, J. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881109103115 · Cited by 27
Hofmann, S. G., Carpenter, J. K., Otto, M. W., Rosenfield, D., Smits, J. A. J., & Pollack, M. H. (2015) · Contemporary Clinical Trials · doi:10.1016/j.cct.2015.06.015 · Cited by 27
Rich, M. T., & Torregrossa, M. M. (2018) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2017.09.003 · Cited by 27
Emotional Learning and Glutamate: Translational Perspectives
Gillespie, C. F., & Ressler, K. J. (2005) · CNS Spectrums · doi:10.1017/s1092852900010439 · Cited by 27
Self-citationWangelin, B. C., Powers, M. B., Smits, J. A. J., & Tuerk, P. W. (2013) · Contemporary Clinical Trials · doi:10.1016/j.cct.2013.08.003 · Cited by 26
Cognitive enhancers for the treatment of anxiety disorders
Hofmann, S. G., Fang, A., & Gutner, C. A. (2014) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-139002 · Cited by 29
Cherry‐Allen, K. M., Lenze, E. J., & Lang, C. E. (2014) · Journal of Neurophysiology · doi:10.1152/jn.00882.2013 · Cited by 28
Risbrough, V. B., Glenn, D. E., & Baker, D. G. (2015) · Current topics in behavioral neurosciences · doi:10.1007/7854_2015_5010 · Cited by 28
New Approaches to Addiction Treatment Based on Learning and Memory
Kiefer, F., & Dinter, C. (2011) · Current topics in behavioral neurosciences · doi:10.1007/7854_2011_147 · Cited by 29
Wu, S., HSU, L., TU, W., Wang, W., HUANG, Y., Pawlak, C. R., & HO, Y. (2007) · Behavioural Brain Research · doi:10.1016/j.bbr.2007.09.013 · Cited by 26
Lu, G., Wu, N., Zhang, Z., Ai, J., & Li, J. (2011) · Neuroscience Letters · doi:10.1016/j.neulet.2011.08.034 · Cited by 26
D‐cycloserine facilitates extinction of cocaine self‐administration in c57 mice
Thanos, P. K., Subrize, M., Lui, W., Puca, Z., Ananth, M. R., Michaelides, M., Wang, G., & Volkow, N. D. (2011) · Synapse · doi:10.1002/syn.20944 · Cited by 26
Back, S. E., Waldrop, A. E., Brady, K. T., & Hien, D. A. (2006) · Brief Treatment and Crisis Intervention · doi:10.1093/brief-treatment/mhl013 · Cited by 26
A HIGH-THROUGHPUT CLINICAL ASSAY FOR TESTING DRUG FACILITATION OF EXPOSURE THERAPY
Rodebaugh, T. L., Levinson, C. A., & Lenze, E. J. (2013) · Depression and Anxiety · doi:10.1002/da.22047 · Cited by 26
Chronic modafinil effects on drug-seeking following methamphetamine self-administration in rats
Reichel, C. M., & See, R. E. (2011) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145711000988 · Cited by 26
Subtype-Specific Agonists for NMDA Receptor Glycine Binding Sites
Maolanon, A. R., Risgaard, R., Wang, S., Snoep, Y., Papangelis, A., Yi, F., Holley, D. C., Barslund, A. F., Svenstrup, N., Hansen, K. B., et al. (2017) · ACS Chemical Neuroscience · doi:10.1021/acschemneuro.7b00117 · Cited by 26
Jessen, M., Frederiksen, K., Yi, F., Clausen, R. P., Hansen, K. B., Bräuner‐Osborne, H., Kilburn, P., & Damholt, A. B. (2017) · Molecular Pharmacology · doi:10.1124/mol.117.108944 · Cited by 26
Donahue, C. B., Kushner, M. G., THURAS, P. D., Murphy, T. G., Demark, J. V., & Adson, D. E. (2008) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2008.12.004 · Cited by 27
Extinction: Behavioral Mechanisms and Their Implications ☆
Bouton, M. E. (2017) · Elsevier eBooks · doi:10.1016/b978-0-12-809324-5.21006-7 · Cited by 25
Byrne, S., Farrell, L. J., & Rapee, R. M. (2011) · Clinical Psychologist · doi:10.1111/j.1742-9552.2011.00005.x · Cited by 25
Kelamangalath, L., & Wagner, J. J. (2010) · Neuroscience · doi:10.1016/j.neuroscience.2010.06.006 · Cited by 25
Tolin, D. F. (2017) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2017.08.007 · Cited by 25
Davis, M. L., Papini, S., Rosenfield, D., Roelofs, K., Kolb, S., Powers, M. B., & Smits, J. A. J. (2017) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2017.09.004 · Cited by 28
Self-citationPharmacotherapy of Anxiety Disorders: Current and Emerging Treatment Options
Garakani, A., Murrough, J. W., Freire, R. C. R., Thom, R. P., Larkin, K., Buono, F. D., & Iosifescu, D. V. (2021) · FOCUS The Journal of Lifelong Learning in Psychiatry · doi:10.1176/appi.focus.19203 · Cited by 29
Yang, F.-Y., Lee, Y.-S., Cherng, C. G., Cheng, L.-Y., Chang, W.-T., Chuang, J., Kao, G.-S., & Yu, L. (2010) · Journal of Psychopharmacology · doi:10.1177/0269881110388333 · Cited by 25
Effects of D-cycloserine on the extinction of appetitive operant learning
Vurbic, D., Gold, B., & Bouton, M. (2011) · Behavioral Neuroscience · doi:10.1037/a0024403 · Cited by 27
Stress enhances the consolidation of extinction memory in a predictive learning task
Hamacher‐Dang, T. C., Engler, H., Schedlowski, M., & Wolf, O. T. (2013) · Frontiers in Behavioral Neuroscience · doi:10.3389/fnbeh.2013.00108 · Cited by 25
Exposure to heights in a theme park: Fear, dizziness, and body sway
Alpers, G. W., & Adolph, D. (2007) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2007.05.008 · Cited by 25
Innovations in the delivery of exposure and response prevention for obsessive-compulsive disorder
Patel, S. R., Comer, J., & Simpson, H. B. (2021) · Current Topics in Behavioral Neurosciences · doi:10.1007/7854_2020_202 · Cited by 24
Laine, M. A., Mitchell, J., Rhyner, J., Clark, R., Kannan, A., Keith, J., Pikus, M., Bergeron, E., Ravaglia, I. C., Ulgenturk, E., et al. (2022) · eNeuro · doi:10.1523/eneuro.0382-22.2022 · Cited by 24
Cryan, J. F., & Dev, K. K. (2008) · Handbook of behavioral neuroscience · doi:10.1016/s1569-7339(07)00013-6 · Cited by 25
An fMRI Study Examining Effects of Acute D-Cycloserine During Symptom Provocation in Spider Phobia
Aupperle, R. L., Hale, L. R., Chambers, R. J., Cain, S., Barth, F. X., Sharp, S., Denney, D. R., & Savage, C. R. (2009) · CNS Spectrums · doi:10.1017/s1092852900024044 · Cited by 24
Ana, E. J. S., Prisciandaro, J. J., Saladin, M. E., McRae‐Clark, A. L., Shaftman, S. R., Nietert, P. J., & Brady, K. T. (2015) · American Journal on Addictions · doi:10.1111/ajad.12191 · Cited by 24
Acute systemic fibroblast growth factor-2 enhances long-term memory in developing rats
Graham, B. M., & Richardson, R. (2009) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2008.12.007 · Cited by 25
Augmentation of Evidence-Based Psychotherapy for PTSD With Cognitive Enhancers
Marin, M., Lonak, S. F., & Milad, M. R. (2015) · Current Psychiatry Reports · doi:10.1007/s11920-015-0582-0 · Cited by 24
Combining alprazolam with systematic desensitization therapy for dental injection phobia
Coldwell, S. E., Wilhelm, F. H., Milgrom, P., Prall, C. W., Getz, T., Spadafora, A., Chiu, I.-Y., Leroux, B. G., & Ramsay, D. S. (2007) · Journal of Anxiety Disorders · doi:10.1016/j.janxdis.2007.01.001 · Cited by 24
de Leeuw, A. S., van Megen, H. J. G. M., Kahn, R. S., & Westenberg, H. G. M. (2016) · European Psychiatry · doi:10.1016/j.eurpsy.2016.06.011 · Cited by 24
The Amygdala and the Neural Pathways of Fear
Dbiec, J., & LeDoux, J. E. (2009) · Humana Press eBooks · doi:10.1007/978-1-60327-329-9_2 · Cited by 27
New Pharmacotherapeutic Approaches to Obsessive-Compulsive Disorder
Figee, M., & Denys, D. A. J. P. (2009) · CNS Spectrums · doi:10.1017/s1092852900027255 · Cited by 24
Lonsdorf, T. B., Haaker, J., Fadai, T., & Kalisch, R. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3338-8 · Cited by 27
Pillay, N., & Stein, D. J. (2007) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.12.4.541 · Cited by 24
Emerging drugs for panic disorder
Perna, G., Guerriero, G., & Caldirola, D. (2011) · Expert Opinion on Emerging Drugs · doi:10.1517/14728214.2011.628313 · Cited by 23
d-Cycloserine enhances the bidirectional range of NMDAR-dependent hippocampal synaptic plasticity
Vestring, S., Dorner, A., Scholliers, J., Ehrenberger, K., Kiss, A., Arenz, L., Theiß, A., Rossner, P., Frase, S., du Vinage, C., et al. (2024) · Translational Psychiatry · doi:10.1038/s41398-023-02725-7 · Cited by 24
Incentive salience: novel treatment strategies for major depression
Soskin, D. P., Holt, D. J., Sacco, G. R., & D, M. F. M. (2013) · CNS Spectrums · doi:10.1017/s1092852913000345 · Cited by 22
Towards Medication-Enhancement of Cognitive Interventions in Schizophrenia
Chou, H., Twamley, E. W., & Swerdlow, N. R. (2012) · Handbook of experimental pharmacology · doi:10.1007/978-3-642-25758-2_4 · Cited by 24
Waddell, J., Mallimo, E. M., & Shors, T. J. (2009) · Neurobiology of Learning and Memory · doi:10.1016/j.nlm.2009.08.002 · Cited by 23
Metadata
- Authors
- Ressler, K. J., Rothbaum, B. O., Tannenbaum, L., Anderson, P., Graap, K., Zimand, E., Hodges, L., & Davis, M.
- Affiliations
- Emory University (US)
- Virtually Better (US)
- University of North Carolina at Charlotte (US)
- Venue
- Archives of General Psychiatry
- Publisher
- American Medical Association (AMA)
- Published
- 2004-11-01
- Volume
- 61
- Issue
- 11
- Pages
- 1136
- ISSN
- 0003-990X (ISSN-L)
- OpenAlex
- W2156900283
- Cited by
- 1,063
- References
- 45
- Citations by year
- 2026: 4 · 2025: 13 · 2024: 14 · 2023: 17 · 2022: 54 · 2021: 20 · 2020: 20 · 2019: 31 · 2018: 35 · 2017: 53 · 2016: 30 · 2015: 52 · 2014: 62 · 2013: 74 · 2012: 79
- FWCI
- 82.58
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Archives of General Psychiatry (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institute of Mental Health (MH-047840, MH069884, K01MH069884)
- Topics
- Social Sciences › Psychology › Experimental and Cognitive Psychology › Anxiety, Depression, Psychometrics, Treatment, Cognitive Processes
- Life Sciences › Neuroscience › Cognitive Neuroscience › Memory and Neural Mechanisms
- Social Sciences › Psychology › Clinical Psychology › Posttraumatic Stress Disorder Research
- Keywords
- D-cycloserine, acrophobia, specific phobia, NMDA receptor partial agonist, fear extinction, virtual reality exposure therapy, nootropic drugs, adjunctive pharmacotherapy, skin conductance, anxiety disorders, fear learning, avoidance behavior, medication adherence
- MeSH terms
- Adult, Combined Modality Therapy, Cycloserine, Desensitization, Psychologic, Double-Blind Method, Extinction, Psychological, Fear, Female, Humans, Male, Middle Aged, Phobic Disorders, Pilot Projects, Placebos, Psychiatric Status Rating Scales, Receptors, N-Methyl-D-Aspartate, Treatment Outcome
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
